GlaxoSmithKline received a warning letter for use of misleading imagery in its television ad for
Avodart. The Feds felt that comparing prostate size to planets might not be a good idea.
Companies are tightening their purse strings just when brand strategies need to target new
audiences
Astellas’s hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board
members and replace them with their own.
Roche raised their bid for the biotech last Friday to $93 dollars per share, luring Genentech back to
the negotiating table.
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some
eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep
Schering’s licensing deals secure. Was it the right move?
CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or
are they just not that into them?
Podcast:Women of the Year-professor to president. Anhal Purohit
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some
eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep
Schering’s licensing deals secure. Was it the right move?
Lawyers from Duane Morris LLP offer their take on the Supreme Court’s groundshaking preemption
decision
Roche raised their bid for the biotech last Friday to $93 dollars per share, luring Genentech back to
the negotiating table.
Powered by Yahoo! Answers